Topics
July/August 2016 | What's New On The Anti-pdgf Front?
An Oral Drug for Treatment of AMD?
The potential for this proposed treatment option could be significant for many patients and their caregivers.
Carl C. Awh, MD
November 17, 2026
MacuMira Receives CE Mark Certification for Retinal Microcurrent Stimulation Device to Treat Dry AMD
November 16, 2026
Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion, Advancing Retinal Disease Pipeline
RetinaLyze System Receives EU MDR Class 2a Certification for Retinal Screening Software
November 11, 2026
AAO, AOA Respond to FDA GLP-1 Drug Labeling Changes, Highlight NAION Risk and Eye Care Recommendations
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Supported by Zeiss
Free Print Subscription
Email Newsletter
Conference Calendar